Artios Pharma to attend the JP Morgan 2020 Healthcare Conference in San Francisco, January 12-16, 2020
CAMBRIDGE, UK and NEW YORK, NEW YORK, 06 January 2020 — Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the company will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
The management team will be in attendance and hosting meetings with partners and investors.
END
For more information, please contact:
Artios Pharma Ltd.
Niall Martin, Chief Executive Officer
Tel: +44 (0)1223 804180
Media & IR Enquiries
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Tel: +44 (0) 203 950 9144
Notes to Editors
About Artios Pharma Limited
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and the National Centre for Biomolecular Research at Masaryk University in the Czech Republic. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers. Backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix, Pfizer Ventures, ipgroup, SV Healthcare and M Ventures.